Inhibitor of tyrosine kinase that is used for treatment of Leukemia and some types of cancer. Excretion intro breast milk is very low, with no problems reported among breastfed infants from treated mothers. Concentration in the mother's milk decreases to one half after 9 hours from the last dose which is a property that could be taken advantage of to minimize the dose transfer to the infant if stopping breastfeeding is not desired. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½). It means wait 16 days after the last dose before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.